Adamis Pharmaceuticals Corp logo

Adamis Pharmaceuticals Corp

$ 0.19 -0.0048 (-2.52%) 10:08 PM EST
P/E:
At Loss
P/B:
9.78
Market Cap:
$ 27.88M
Enterprise V:
$ 25.89M
Volume:
249.32K
Avg Vol (2M):
2.28M
Also Trade In:
Volume:
249.32K
Market Cap $:
27.88M
PE Ratio:
At Loss
Avg Vol (2-Month):
2.28M
Enterprise Value $:
25.89M
PB Ratio:
9.78
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Name Current Vs Industry Vs History
Cash-To-Debt 5.6
Equity-to-Asset 0.23
Debt-to-Equity 0.15
Debt-to-EBITDA -0.02
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -41.02
Distress
Grey
Safe
Beneish M-Score -3.79
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 45.42
9-Day RSI 54.27
14-Day RSI 53.13
6-1 Month Momentum % -67.11
12-1 Month Momentum % -83.35

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.14
Quick Ratio 1.01
Cash Ratio 0.27
Days Inventory 33.1
Days Sales Outstanding 258.84
Days Payable 279.3

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -46.8

Financials (Next Earnings Date:2023-02-22 Est.)

ADMP's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ADMP

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 1.542
EPS (TTM) ($) -0.22
Beta 0.78
Volatility % 65
14-Day RSI 53.13
14-Day ATR ($) 0.019438
20-Day SMA ($) 0.16752
12-1 Month Momentum % -83.35
52-Week Range ($) 0.12 - 0.8477
Shares Outstanding (Mil) 149.98

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Adamis Pharmaceuticals Corp Filings

Document Form Filing Date
No Filing Data

Adamis Pharmaceuticals Corp Analysis

Share your research

Headlines

See More
No news.